FIGURE

Figure 5

ID

ZDB-FIG-230501-68

Publication

Yin et al., 2023 - Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery

Other Figures

All Figure Page

Back to All Figure Page

Figure 5

Navitoclax and everolimus and the combination of both chemotherapeutic agents reduced spUM-LB008 tumor burden in zf-PDX model. (a) The experimental layout of drug treatment in the UM zf-PDX model. (b) Representative phenotypes of zebrafish in the DMSO-control and drug treatment groups at 6 dpi (n = 3, p < 0.01). P values were indicated as follows: ** p < 0.01, *** p < 0.001, **** p < 0.0001. (c) Effect of navitoclax, everolimus, and their combination treatment on tumor burden, compared to the control group. The combination of navitoclax and everolimus reduced the tumor burden significantly compared to everolimus and navitoclax alone. The fluorescence intensity in CHT (white rectangle) of each individual zebrafish was measured as the metastasized tumor burden. The scale bar is 500 µm.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Pharmaceuticals (Basel)